Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK–YAP signaling axis

Yusuke Goto1 · Toshinori Ando1,2 · Hiroki Izumi1 · Xiaodong Feng1,3 · Nadia Arang1 · Mara Gilardi1 · Zhiyong Wang1 · Kazuyo Ando1,4 · J. Silvio Gutkind1

Received: 6 September 2019 / Revised: 10 March 2020 / Accepted: 12 March 2020 / Published online: 23 March 2020
© The Author(s), under exclusive licence to Springer Nature Limited 2020

Abstract
Prostate cancer (PCa) innervation contributes to the progression of PCa. However, the precise impact of innervation on PCa cells is still poorly understood. By focusing on muscarinic receptors, which are activated by the nerve-derived neurotransmitter acetylcholine, we show that muscarinic receptors 1 and 3 (m1 and m3) are highly expressed in PCa clinical specimens compared with all other cancer types, and that amplification or gain of their corresponding encoding genes (CHRM1 and CHRM3, respectively) represent a worse prognostic factor for PCa progression free survival. Moreover, m1 and m3 gene gain or amplification is frequent in castration-resistant PCa (CRPC) compared with hormone-sensitive PCa (HSPC) specimens. This was reflected in HSPC-derived cells, which show aberrantly high expression of m1 and m3 under androgen deprivation mimicking castration and androgen receptor inhibition. We also show that pharmacological activation of m1 and m3 signaling is sufficient to induce the castration-resistant growth of PCa cells. Mechanistically, we found that m1 and m3 stimulation induces YAP activation through FAK, whose encoding gene, PTK2 is frequently amplified in CRPC cases. Pharmacological inhibition of FAK and knockdown of YAP abolished m1 and m3-induced castration-resistant growth of PCa cells. Our findings provide novel therapeutic opportunities for muscarinic-signal-driven CRPC progression by targeting the FAK–YAP signaling axis.

Introduction
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second most frequent cause of cancer related death among men in the USA, which accounts for 10% of all estimated new deaths of cancer among men [1]. More than 95% of PCa is originally sensitive to androgen deprivation therapy, namely surgical castration, pharmacological castration, and androgen receptor (AR) inhibitors; however, PCa eventually gains resistance to these hormonal therapy [2]. This state is referred to as castration-resistant PCa (CRPC). Several treatment options such as new generation AR inhibitors, chemotherapeutic agents, and immunomodulatory agents were newly approved for CRPC in this decade, however, CRPC is still poorly controlled and often a fatal disease.

A recent breakthrough in PCa basic research was the discovery of the contribution of nerves in stromal tissues in the progression of PCa [3–5]. Stromal adrenergic fibers were shown to induce early phase development of PCa, while cholinergic fibers induce invasion and metastasis of PCa [5]. This is consistent with several clinical findings: spinal cord injured patients have lower incidence of PCa [6, 7], β-blocker users have reduced PCa-specific mortality in patients with high-risk or metastatic disease at the time of diagnosis [8], and the incidence rates of PCa decreases with increasing cumulative dose of antimuscarinic agents for...
overinnervation on cancer cells are still unclear. A previous study showed autocrine activation of cholinergic receptor muscarinic 3 (CHRM3) in PCa cells [10]; yet, the precise mechanisms of muscarinic signaling on PCa cells are poorly defined.

In this study, we characterized the expression of cholinergic receptor muscarinic 1 (CHRM1; m1) and CHRM3 (m3) receptors in hormone-sensitive PCa (HSPC) and CRPC clinical specimens and PCa-derived cell lines, to determine how signaling by these receptors affect growth under castrated conditions. We next dissected downstream signaling of these receptors to identify new druggable targets. We show that m1 or m3 activation induce the castration-resistant growth of PCa cells, and that this process requires the activation of YAP, a transcriptional co-activator regulated by the Hippo pathway. In turn, we found that m1 and m3 receptors stimulate YAP through the focal adhesion kinase (FAK). Pharmacological inhibition of FAK-prevented YAP activation induced by m1 and m3 receptors, and consequently inhibited castration-resistant growth of PCa cells. Overall, our results suggest that FAK represents as potential therapeutic target for the treatment of innervation-driven castration-resistant growth of PCa.

Results

Transcripts for m1 and m3 are upregulated in PCa, and their genes are frequently amplified or gained in CRPC

To explore the importance of m1 and m3 in PCa, we first investigated m1 and m3 mRNA expression in The Cancer Gene Atlas (TCGA) pan cancer expression analysis by RNA-seq, including 31 different cancer types and 10858 clinical specimens. Compared with all other cancer types, prostate adenocarcinoma (PRAD) had the highest expression of m1, and fifth highest expression of m3 (Fig. 1a). Since CRPC is a clinically challenging condition of PCa and TCGA-PRAD samples are all classified as HSPC, we next combined 12 different clinical cohorts consisting of 1487 PCa specimens to analyze copy number alterations (CNA) as PCa gains hormone resistance, namely, HSPC, CRPC, and neuroendocrine PCa (NEPC), the latter a highly aggressive form of CRPC. Remarkably, m1 amplification or gain were significantly frequent in CRPC and NEPC ($P < 0.001$), and m3 amplification or gain were also significantly frequent in CRPC and NEPC ($P < 0.001$) compared with HSPC specimens (Fig. 1b). We also performed a cross-cancer analysis approach with 52,438 clinical tissues for m1 and m3 CNA, and found that several PCa cohorts have high amplification frequency of m1 and m3 among 184 cohorts (Supplementary Fig. 1A, B). Of interest, we found that the expression of m1 and m3 is significantly higher when compared with other muscarinic receptors (m2, m4, and m5) in PCa tissues (Supplementary Fig. 1C). Furthermore, m1 and m3 amplification or gain represent a worse prognostic factor for progression free survival of PCa patients (Fig. 1c). When we stratify patients by Gleason score, which is a histological grade based on PCa tissue histology, patients with aggressive PCa whose Gleason score were 8, 9, or 10 have significantly higher copy number alteration compared with the patients with Gleason score 7 patients (Fig. 1d). These findings suggest a possible oncogenic role for m1 and m3 receptors in PCa, especially CRPC.

m1 and m3 are highly expressed in CRPC cell lines, and activation of m1 and m3 is sufficient to induce castration-resistant growth of PCa cells

We next investigated expression of m1 and m3 in PCa cell lines. We used LNCaP cell line as a typical castration and AR inhibitor sensitive cell line, and MDAPCa2b as a castration sensitive, but AR inhibitor resistant cell line [11]. As CRPC cell lines, we used 22Rv1 which expresses AR, and PC3 which does not express AR [12]. qPCR analysis of m1 and m3 revealed increase of m1 and m3 expression progressively as the cells become resistant to castration or AR inhibitors (Fig. 2a). Furthermore, we performed immunofluorescence (IF) for m1 and m3 protein in these cell lines, which showed that m1 and m3 protein expression levels increase as cells become castration resistant, similar to mRNA levels (Supplementary Fig. 1D). Consistent with these data, pharmacological activation of m1 and m3 by a synthetic muscarinic agonist carbachol for 5 min showed rapid pERK (T202/Y204) elevation in MDAPCa2b, 22Rv1, and PC3, but not in LNCaP (Fig. 2b and Supplementary Fig. 2A). Since early studies have suggested that m1 and m3 may exert oncogenic roles [13], we stimulated these cells with different concentrations of carbachol under castrated conditions (charcoal stripped serum; CSS) [14]. Of interest, carbachol-induced increase of viability in MDAPCa2b, 22Rv1 and PC3, but not in LNCaP (Fig. 2c).

As both m1 and m3 are G-protein coupled receptors (GPCRs) that are coupled to Goq, we engineered PCa cell lines stably expressing a synthetic Gq-coupled GPCR (DREADD-Gq) for LNCaP and 22Rv1; LNCaP-DREADDGq and 22Rv1-DREADD-Gq, respectively. This DREADD-Gq was developed based on the m3 receptor, and is mutated so that it cannot be activated by its natural ligand (acetylcholine), but gained the ability to be activated only by a synthetic ligand, Clozapine N-oxide (CNO) [15]. This synthetic biology system can circumvent the known variability of GPCR expression levels and the presence of potential autocrine loops that would result in variable basal GPCR
activity, and consequently, it can facilitate the analysis of the effects of Gq activation in PCa cells. Treatment with CNO in LNCaP-DREADD-Gq cells induced increased cell viability under FBS medium, CSS medium as well as in CSS + enzalutamide (ENZ) medium. Similarly, CNO treatment in 22Rv1-DREADD-Gq cells showed increase in viability under the same conditions, CSS medium, and CSS + ENZ medium (Fig. 2d). These data support that activation of Gq signaling in cancers by m1 and m3 stimulation can induce castration-resistant growth of PCa cells.

Next, we tested m1 and m3 expression in LNCaP cells after treatment with CSS + ENZ. Treatment of LNCaP cells with CSS + ENZ for up to 3 weeks resulted in a time-dependent increase of m1 and m3, and decrease of prostate
specific antigen (PSA) (Fig. 2e). We next asked if these CSS + ENZ treated cells can respond to carbachol in terms of viability under androgen deprivation mimicking castration. As shown in Fig. 2f, 1 week treated LNCaP (CSS + ENZ-LNCaP) cells gained the ability to grow with carbachol. Mechanistically, we investigated the activation of ERK as measured by pERK accumulation after stimulation by carbachol, and found that CSS + ENZ-LNCaP cells could respond to carbachol in a dose-dependent manner as shown by increase in pERK, but no response was observed in wild-type LNCaP cells (Fig. 2g and Supplementary Fig. 2B). To dissect the role of m1 and m3 in mitogenic signaling, we used siRNAs for m1 and m3 to knockdown each receptor, using PC3 cells that show high m1 and m3 expression compared with other cell lines (Fig. 2a). Knockdown of m1 and m3 showed reduction of pERK in response to carbachol (Supplementary Fig. 3A–C). Furthermore, to investigate the effect of activation of other GPCRs, we stimulated LNCaP cells with LPA and thrombin, which showed a slight increase in pERK signal, similar to the response to carbachol (Supplementary Fig. 4A and B). Our recent study confirmed that DREADD-Gq is primarily selective for Gq proteins, similar to m1 and m3 [16]. However, to examine the possible contribution of β-Arestins to Gq-mediated mitogenic signaling, we knocked down β-Arestin1/2 in 22Rv1-DREADD-Gq cells, and stimulated with CNO. As shown in Supplementary Fig. 4C, D, knockdown of β-Arestin did not change pERK levels induced by CNO, which suggests β-Arestin may not contribute the Gq-mediated mitogenic signaling in PCa cells. Together, these results support that stimulation of m1 and m3 receptors can support the castration-resistant growth of PCa cells.

Oncogenic m1 and m3 signaling activates FAK and YAP

We have recently reported YAP activation promoted by the GNAQ oncogene, encoding constitutively active Gq, in uveal melanoma [17]. Thus, we hypothesized m1 and m3 stimulation could induce FAK and YAP activation by a similar mechanism in PCa. After treatment with carbachol, 22Rv1 cells showed clear activation of YAP, which was assessed by decrease of serine phosphorylated YAP (S127), and increase of tyrosine phosphorylation of YAP (Y357), which are typical YAP-regulated genes, after carbachol stimulation for these assays. CNO treatment induced a decrease of pFAK and pERK (Fig. 3d and Supplementary Fig. 5B). Concomitantly, we could also see the increase of pFAK (Y397), the active tyrosine phosphorylated form of FAK [16], with carbachol-induced FAK activation (Supplementary Fig. 6). Together, these findings support that stimulation of m1 and m3 receptors can support the castration-resistant growth of PCa cells.
suggest that m1 and m3 activate FAK and YAP, and that this may provide a mechanism for castration-resistant growth induced by m1 and m3 activation.

Next, we asked if YAP knockdown is sufficient to rescue the effect of castration-resistant growth of PCa cells. After confirming knockdown efficiency using siRNAs targeting YAP (si-YAP), we knocked down YAP in 22Rv1 and PC3 together with carbachol stimulation. As shown in Fig. 3g and Supplementary Fig. 7A, YAP knockdown reverted the effect of carbachol on castration-resistant growth. This suggests that YAP functions as a key effector for castration-resistant growth induced by m1 and m3 stimulation.
LNCaP cells are treated with 5% CSS (ANOVA). t1 + CSS 1 μM ENZ, cells are subjected to viability assay. CSS 10 μM carbachol for 5 min, and subjected to Western blotting. MDAPCa2b, 22Rv1, and PC3 showed increase in pERK with carbachol, but no increase was observed for LNCaP. e Cell viability in response to carbachol. PCa cells were treated with different concentrations of carbachol for 72 h. LNCaP did not respond to carbachol, but MDAPCa2b, 22Rv1, and PC3 showed an increase in viability with carbachol. Bars represent average ±SEM (N = 4). f Cell viability in response to carbachol before and after CSS + ENZ treatment. After 1 week of 5% CSS + 10 μM ENZ cells are subjected to viability assay. CSS + ENZ treated cells increased viability with carbachol, but no response was seen for cells under basal conditions. Bars represent average ±SEM (N = 4). g Response to carbachol before and after CSS + ENZ in LNCaP. pERK increase was seen in CSS + ENZ treated LNCaP with 100 μM carbachol, but no difference in pERK was observed for LNCaP cells under basal conditions.

PTK2, the FAK gene, is frequently amplified and gained in CRPC, and m1 or m3 amplified patients harbor frequent FAK gene copy number increase

As we found that FAK–YAP activation can provide a mechanism for castration-resistant growth of PCa cells induced by m1 and m3 activation, we next investigated the relevance of FAK in clinical PCa specimens. First, we applied a cross-cancer approach with 52438 clinical tissues to investigate CNAs in the gene encoding FAK, PTK2 (herein referred as FAK). Among them, FAK copy number data were available for 20531 tissues, in which we assessed FAK amplification frequency in different cohorts. Among 184 cohorts, 26 cohorts showed FAK amplification more than 5%. Interestingly, six cohorts with PCa patients (Neuroendocrine Prostate Cancer, Multi-Institute, Nat Med 2016; Prostate Adenocarcinoma, Fred Hutchinson CRC, Nat Med 2016; Metastatic Prostate Adenocarcinoma, MCTP, Nature 2012; Metastatic Prostate Cancer, SU2C/PCF Dream Team, Cell 2015; Prostate Adenocarcinoma, MSKCC/DFCI, Nature Genetics 2018; and Prostate Adenocarcinoma, TCGA, Provisional) were ranked as highly amplified cohorts (Fig. 4a). We next asked whether FAK CNA correlates with castration-resistance, for which 1487 PCa samples were subjected to analysis for FAK gene amplification or gain. Remarkably, FAK amplification was more frequent in CRPC and NEPC than in HSPC, and FAK gain was also more frequent in CRPC and NEPC than in HSPC (Fig. 4b). Moreover, FAK expression was significantly higher in patients with more aggressive disease, measured by a Gleason score of 8, 9, or 10 compared with patients with Gleason score of 6 or 7. Similarly, FAK expression was significantly higher in patients with larger tumors, T3 and T4, as compared with T2, and higher in patients with lymph node invasion, N1, when compared with patients in which no lymph node invasion was detected, N0 (Fig. 4c). Moreover, high expression of FAK was a worse prognostic factor for patients with PCa (Fig. 4d).

Interestingly, patients with m1 or m3 amplification had more FAK copy number gains, and patients with m1 or m3 gain had higher FAK copy number, compared with patients without m1 and m3 amplification or gain (Fig. 4e). These data suggest a critical role of FAK in PCa progression, especially CRPC, and raise the possibility of an active role for m1-m3-FAK signaling in clinical PCa specimens.

YAP is activated through FAK, and FAK inhibitor can inhibit carbachol-induced castration-resistant growth of PCa cells

The impact of m1–m3 FAK–YAP signaling in PCa cells and specimens prompted us to evaluate the possibility of the pharmacological intervention on FAK as a therapeutic venue in CRPC. VS-4718, an orally available FAK inhibitor (FAKi) was used in this study. To study the effect of FAK inhibition on YAP signaling, we assessed whether FAKi could inhibit the activation of YAP induced by carbachol. 22Rv1 cells were treated with FAKi, carbachol or both. Carbachol treatment induced tyrosine phosphorylation of FAK (Y397) and YAP (Y357), and CTGF and CYR61 elevation. These effects were abolished by the addition of FAKi; however, FAKi did not prevent an increase in pERK, suggesting that FAK does not affect canonical signaling downstream of Gq to ERK, consistent with our previous report [17] (Fig. 5a and Supplementary Fig. 7B). Similarly, FAKi could block upregulation of CTGF and CYR61, which were induced by carbachol (Fig. 5b). Next, we tested the potential of FAK inhibition for CRPC treatment. We treated 22Rv1 and PC3 with carbachol with or without FAKi. Remarkably, FAKi blocked castration-resistant growth of 22Rv1 and PC3 cells induced by carbachol (Fig. 5c). We also used 22Rv1-DREADD-Gq cells to investigate whether Gq activation by CNO and its induction of viability can be blocked by FAKi. Similar to the results with carbachol, the...
increase of viability in 22Rv1-DREADD-Gq cells by CNO was abolished by FAKi (Fig. 5d). Finally, we used cell sphere assays to study the effects of FAKi in conditions that better reflect the in vivo situation. FAKi could significantly block the sphere formation in PC3 and 22Rv1-DREADD-Gq cell lines in terms of sphere number and area, and Gq
stimulation by carbachol or CNO induced significantly higher number of spheres in PC3 and 22Rv1-DREADD-Gq cells, respectively. Furthermore, CNO or carbachol-induced sphere formation was abolished by co-administration of FAKi (Fig. 5e).

Discussion

Muscarinic GPCRs were first shown to possess ligand-dependent oncogenic function in 1991 [13]. In this early study, carbachol stimulation of m1, m3, and m5 receptors stably expressing NIH3T3 cells but not m2 and m4 receptors resulted in the ability to induce strong cellular transformation [13]. Since this initial discovery, alteration of G proteins and GPCRs by mutation or aberrant expression have been found to be involved in cancer initiation and progression across a wide range of cancer types [18, 19]. In PCa, a previous elegant innervation-driven tumor progression models using PC3 xenograft showed distant metastasis and poor survival outcome in Chrm1−/− mice compared with Chrm1+/+ mice [5]. In line with these findings, as an origin of neural signaling, it was reported that nerve progenitor cells from the subventricular zone of the mouse brain migrate into blood vessels, and give rise to nerve cells surrounding PCa cells [3]. These findings support the possibility of PCa progression through neural signaling, albeit the underlying cellular and molecular mechanisms were not explored. Toward this end, we now show a direct pronocogenic effect of m1 and m3 receptor activation in PCa cells, especially contributing to the castration-resistant growth of PCa, which is the most challenging state of PCa in the clinical setting.

We observed increased expression of m1 and m3 mRNA after CSS and enzalutamide treatment in LNCaP cells in a time-dependent manner, concomitant with increased response to carbachol in terms of signaling and viability. This represents a gain of function upon AR inhibition, given that the original LNCaP cells do not respond to carbachol neither in regards to signaling nor in viability. Interestingly, using publicly available PCa datasets, we showed that m1 and m3 are amplified and gained in CRPC when Compared with HSPC clinical specimen. This suggests that when HSPC are treated with androgen deprivation therapy, the cancer cells may gain other signaling properties to survive in low-androgen condition, and that one of these critical signals may be provided by innervation-driven muscarinic receptor activation.

In this regard, the adaptive and compensatory mechanisms driving proliferation in PCa under androgen deprivation have been extensively studied. Such mechanisms that bypass AR signaling have been found to involve the activation of Src kinase [20, 21], glucocorticoid receptor [22], PI3K–PTEN signaling [23, 24], and FGFR–MAPK signaling [25]. As for muscarinic signaling, previous reports have shown that carbachol-induced DNA synthesis and proliferation of PCa cells [10, 26–28], consistent with our data. In addition, several ligands for GPCRs were reported to promote mitogenic signaling in PCa, such as angiotensin, bombesin, bradykinin, and lysophosphatidic acid [29], many of which bind to and activate Gq-coupled GPCRs. Interestingly, the blockade of Gq activation by Regulator of G-protein signaling 2 (RGS2) was reported to block androgen-independent growth of LNCaP cells [30]. Although how m1 and m3 are upregulated under androgen deprivation is unclear, these changes can provide a novel mechanism driving castration-resistant growth.

Mechanistically, we showed Hippo–YAP signaling axis is potently activated after stimulation of m1 and m3 with carbachol. Recently, the contribution of YAP to castration-resistant growth has been reported by several studies. One study showed a direct interaction between YAP1 and AR is the only drug approved by FDA that can target YAP signaling axis in castration-resistant growth of PCa. Verteporfin is the only drug approved by FDA that can target YAP by inhibiting the interaction between YAP and TEAD [31]. However, Verteporfin has high systemic toxicities after prolonged use [34], and recent studies have revealed an off-target activity of Verteporfin as an autophagosome inhibitor by promoting oligomerization of p62, which can explain its systemic toxicities [35–37]. In this context, the discovery of novel druggable targets for YAP-induced castration-resistant growth of PCa is urgently
needed. Our group recently reported FAK as one of the druggable targets against YAP activity in uveal melanoma, which has activating mutations in \(GNAQ\) or in \(GNA11\). This previous work prompted us to hypothesize FAK as potential target for PCa proliferation induced by activated muscarinic receptors.
In this study, we showed that pharmacological inhibition of FAK could abolish the activation of YAP, and subsequent castration-resistant growth of PCa cells induced by carbachol treatment. Remarkably, we found that FAK is frequently amplified and gained in CRPC clinical tissues, and that FAK serves as a prognostic factor in PCa. Previously, VS-6062 (alternatively PF-562,271), another small molecule ATP-competitive FAK inhibitor, was reported to have good antitumor effects on PCa xenografts using PC-3M cells [38]. Interestingly, using the transgenic adenocarcinoma of mouse prostate mouse model, VS-6062 did not alter the progression to adenocarcinoma, but continued FAK expression was essential for androgen-independent formation of neuroendocrine carcinoma [39]. This fact is consistent with our results, suggesting that innervation-activated FAK may contribute to castration-resistant growth of PCa. One phase I clinical trial was conducted using VS-6062 in PCa patients, and the drug was well-tolerated [40]. VS-4718, which we used in this study and is also currently in phase I, and VS-6063, another FAK inhibitor in phase I/1b and II [41]. Thus, FAKi is promising therapeutic targets for CRPC.

In summary, we show that muscarinic receptor activation induces castration-resistant growth of PCa cells, this activation leads to phosphorylation of FAK, nuclear translocation of YAP, and that the m1 and m3 stimulated castration-resistant growth and YAP activation could be abolished by FAK inhibition. Ultimately, our findings support that innervation induced PCa castration growth can be inhibited by FAK blockade, and that m1, m3, and FAK targeting may represent a new therapeutic strategy for CRPC.

Materials and methods

Cell lines, culture conditions, and chemicals

LNCaP, MDAPCa2b, 22Rv1, and PC3 cell lines were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were tested for mycoplasma contamination. LNCaP, 22Rv1, and PC3 were cultured in RPMI-1640 (R8758, Sigma-Aldrich, St. Louis, MO, USA), 10% fetal bovine serum (FBS) (F2442, Sigma-Aldrich), 5% CO2, at 37 °C, 1% penicillin/streptomycin (#15140122, Thermo Fisher Scientific, Waltham, MA, USA). For castrated condition, cells were cultured in RPMI-1640 without phenol-red (#11835030, Thermo Fisher Scientific), 5% CSS (#F6765, Sigma-Aldrich). MDAPCa2b were maintained in F-12K (#21127022, Thermo Fisher Scientific) Supplemented with 20% FBS, 25 ng/mL cholera toxin (#C8052, Sigma-Aldrich), 10 ng/mL mouse EGF (#354010, Corning, Corning, NY, USA), 5 μM phosphoethanolamine (#P0503, Sigma-Aldrich), 45 nM sodium selenite (#9133, Sigma-Aldrich), and 5 μg/mL human recombinant insulin (#12585014, Life Technologies, Carlsbad, CA, USA). For castrated conditions, 20% of CSS was used instead of FBS. Carbachol was purchased from Sigma-Aldrich (#C4382). Enzalutamide (#S1250) and VS-4718 (S7653) were purchased from Selleckchem (Houston, TX, USA), CNO was purchased from Sigma-Aldrich (#C0832), thrombin was purchased from Millipore Sigma (605190), LPA was purchased from Sigma-Aldrich (L7260).

siRNA and transfection

SiRNAs SMARTpool siGENOME YAP1 was purchased from Dharmacon (#M-012200-00-0005) (Lafayette, CO, USA), siRNA for β-Arrestin1 was purchased from Qiagen (mix of FlexiTube siRNA #SI02643977 and SI02776921), siRNA for β-Arrestin 2 was purchased from Qiagen (mix of FlexiTube siRNA #SI02776928 and SI03054254), siRNA for m1 was purchased from Sigma-Aldrich (mix of SASI_Hs01_00076783 and SASI_Hs01_00076782), siRNA for m3 was purchased from Sigma-Aldrich (mix of SASI_Hs01_00112285 and SASI_Hs01_00112284), and non-targeting control was from Sigma-Aldrich (#SIC-001). All cells were transfected using Lipofectamine® RNAiMAX

Fig. 4 Clinical impact of FAK gene expression on PCa. a Cross-cancer analysis with 52,438 clinical tissues for FAK gene copy number alterations. In 184 studies with 20531 specimens that FAK copy number data were available, 26 cohorts showed FAK gene amplification in more than 5% of the cases. 6 cohorts (Neuroendocrine Prostate Cancer, Multi-Institute, Nat Med 2016; Prostate Adenocarcinoma, Fred Hutchinson CRC, Nat Med 2016; Metastatic Prostate Adenocarcinoma, MCTP, Nature 2012; Metastatic Prostate Cancer, SU2C/ PCF Dream Team, Cell 2015; and Prostate Adenocarcinoma, MSKCC/DFCI, Nature Genetics 2018; Prostate Adenocarcinoma, TCGA, Provisional) with PCa patients were ranked as highly FAK gene amplified cohorts. b Analysis of PCa cohorts (n = 1487) revealed that NEPC or CRPC specimens had significantly higher amplification or gain of the FAK gene compared with HSPC specimens. ***P < 0.001 (Fisher’s exact test). c Association between mRNA expression of FAK, encoded by PTK2, and Gleason score, T stage and N stage in PCa. Higher mRNA expression of PTK2 was associated with higher Gleason score, T stage, and N stage. Patients with available clinical data and PTK2 mRNA data are extracted from TCGA-PRAD database, and divided into Gleason score 6 (n = 45), 7 (n = 247), and 8, 9, 10 (n = 206). Similarly, data-available cases are divided into T stage T2 (n = 187), and T3, T4 (n = 304), and into N stage N0 (n = 418) and N1 (n = 80). ***P < 0.001 (One-way ANOVA). d Progression free survival of PCa patients and PTK2 expression. Patients with higher expression of PTK2 (z score > 2) showed poorer outcome of progression free survival compared with patients with lower expression of FAK (z score < 2). Log-rank P = 0.0048. e Comparison of FAK gene copy number alteration and m1 or m3 gene amplification, gain. In m1 or m3 gene amplified tissues (n = 47), or m1 or m3 gene gained tissues (n = 223), PTK2 copy number was significantly higher compared with other tissues (n = 1217). ***P < 0.001 (One-way ANOVA).
A. FAKi + carbachol: WB

22Rv1

|                 | VS-4718 | Carbachol |
|-----------------|---------|-----------|
| pFAK (Y397)     | -       | +         |
| FAK             | -       | +         |
| pYAP (Y357)     | -       | +         |
| pYAP (S127)     | -       | +         |
| YAP             | -       | +         |
| CTGF            | -       | +         |
| CYR61           | -       | +         |
| pERK            | -       | +         |
| ERK             | -       | +         |
| GAPDH           | -       | +         |

B. FAKi + carbachol: qPCR

22Rv1

| mRNA expression | VS-4718 | Carbachol |
|-----------------|---------|-----------|
| CTGF            | ***     | ***       |
| CYR61           | ***     | ***       |

C. FAKi on carbachol-induced proliferation

22Rv1

| Cell viability (%) | VS-4718 1μM | VS-4718 10μM |
|--------------------|-------------|--------------|
| control            | -           | -            |
| VS-4718            | +           | +            |

D. FAKi on Gq-induced proliferation

22Rv1-DREADD Gq

| Cell viability (%) | CNO 1μM | VS-4718 1μM | VS-4718 10μM |
|--------------------|---------|-------------|--------------|
| control            | -       | -           | -            |
| VS-4718            | +       | +           | +            |

E. FAKi and carbachol or Gq activation on CRPC cells in 3-D culture

PC3

| Sphere numbers relative to control | VS-4718 | Carbachol |
|------------------------------------|---------|-----------|
|                                   | -       | +         |

22Rv1-DREADD Gq

| Sphere numbers relative to control | CNO | VS-4718 |
|------------------------------------|-----|---------|
|                                   | -   | +       |
**Fig. 5** Pharmacological inhibition of FAK blocks carbamol-induced YAP activation and proliferation. a Treatment with FAK inhibitor can block YAP activation induced by carbamol at the protein level. 22Rv1 cells are treated with 10 μM of VS-4718 for 2 h, treated with 30 μM of carbamol for 1 h, or both. Carbamol-induced tyrosine phosphorylation of FAK (Y397), tyrosine phosphorylation of YAP (Y337), CTGF increase, and CYR61 increase, all of which were abolished by treatment together with VS-4718. pERK induction by carbamol was not blocked by VS-4718. b FAK inhibitor can block CTGF and CYR61 increase induced by carbamol. 22Rv1 cells are treated with 10 μM of VS-4718 for 2 h, treated with 30 μM of carbamol for 1 h, or both. Carbamol-induced increase of CTGF and CYR61 as assessed by qPCR, and this increase was blocked by treatment together with VS-4718. Bars represent average ± SEM (N = 4). **P < 0.01.***P < 0.001 (One-way ANOVA). e FAKi could block PCa cell proliferation induced by carbamol. 22Rv1 and PC3 cells were treated with VS-4718 with indicated concentration for 2 h, and stimulated with different concentrations of carbamol for 72 h. VS-4718 could block PCa cell proliferation induced by carbamol. Bars represent average ± SEM (N = 4). ***P < 0.01. +++P < 0.001 (One-way ANOVA). f FAKi could block carbamol or Gq activation on CRPC cell sphere formation in 3-D culture. Gq stimulation by carbamol or CNO on DREADD-Gq-induced significantly higher number of cell spheres in PC3 and 22Rv1-DREADD-Gq cells, respectively. FAKi could significantly reduce the 3-D growth (spheres) of both PC3 and 22Rv1 CRPC cells in terms of sphere number and area. Furthermore, CNO or Carbachol-induced sphere formation was abolished by co-administration of FAKi. Bars represent average ± SEM (N = 15). *P < 0.05, **P < 0.01, ***P < 0.001 (t test).

**Antibodies and reagents**

Antibodies against YAP1 (#14074), pYAP(S127) (#4911), FAK (#3285), pFAK(Y397) (#8556), pERK (#4370), ERK (#9102), β-Arrestin1/2 (#4674), β-Actin (#4967), and GAPDH (#2118) were purchased from Cell Signaling Technology (Beverly, MA, USA). pYAP(Y357) (#ab62751) and CHRM3 (ab126168) was purchased from Abcam (Cambridge, UK). CHRM1 (#abp1-87466) was purchased from Novus Biologicals, LLC (Centennial, CO, USA).

**Cell viability assay**

Cells in 96-well plates were treated as indicated. LNCaP cells and MDAPCa2b cells were seeded on 96-well plates coated with poly-D lysine (#P7280, Sigma-Aldrich). After treatment, culture medium was Supplemented with 1/100 of the culture volume of Aquabluer reagent (#6015, Multi-Target Pharmaceuticals LLC, Colorado Springs, CO, USA) for 1 h to 4 h. Absorbances were recorded at 570 nm in a Biotek Synergy Neo microplate reader.

**Sphere assay**

Cells were seeded in 96-well ultra-low attachment plate (#CLS3474, Corning, Tewksbury, MA) at 50 cells/well with sphere medium consisted of DMEM/F12 Glutamax (#10565042, Thermo Fisher Scientific), 20 ng/mL basic fibroblast growth factor (#13256029, Thermo Fisher Scientific), 20 ng/mL epithelial growth factor (#PHG0313, Thermo Fisher Scientific), B-27 (#17504044, Thermo Fisher Scientific), and N2 Supplement (#17502-048, Thermo Fisher Scientific). Drug was added at the time cells were seeded. After 14 days, the numbers of sphere colonies which are larger than 20 μm were counted under microscope.

**DNA constructs**

pLenti-Gq-DREADD-neo was cloned from pENTR-Gq-DREADD and pLenti CMV Neo DEST (705–1) by gateway cloning. pENTR-Gq-DREADD was cloned from pCEFL-Gq-DREADD [17]. pLenti CMV Neo DEST (705–1) was a gift from Eric Campeau & Paul Kaufman (Addgene plasmid #17392; http://n2t.net/addgene:17392; RRID:Addgene_17392).

**Immunofluorescence**

Cells cultured on coverslips were washed with phosphate-buffered saline (PBS), fixed with 4% formaldehyde in PBS for 30 min, and permeabilized using 0.05% Triton X-100 for 10 min. Fixed cells were blocked with 3% BSA-containing PBS for 30 min, and incubated with YAP antibody (#14074, Cell Signaling Technology) in 3% BSA-PBS for 1 h at room temperature. The reaction was visualized with Alexa-labeled secondary antibodies (Invitrogen, Carlsbad, CA, USA). SelectFX Nuclear Labeling Kit was used for nuclear staining (#S33025, Invitrogen). Images were acquired with an Axio Imager Z1 microscope equipped with ApoTome system controlled by ZEN 2012 software (Carl Zeiss, Oberkochen, Germany).

**Single cell protein quantification**

Imaging for at least 3 regions of interest (ROI) for each treatment was acquired using LSM 880 airy scan, and images were processed with ZEN software. Qupath software was used to quantify single cells fluorescence intensity for each marker [42], and average single cell fluorescence intensity for each ROI was calculated.

**Quantitative PCR**

RNA was extracted from exponentially growing cultures by the RNeasy Mini Kit following manufacturer’s instructions.
recommendations (#74104, Qiagen, Hilden, Germany). Five hundred nanograms total RNA was converted to cDNA using SuperScript™ VILO™ cDNA Synthesis Kit (#11754250, Thermo Fisher Scientific). qPCR were performed using SYBR™ Select Master Mix (#4472908, Thermo Fisher Scientific). GAPDH was used for normalization. The following primers were used for qPCR. GAPDH fwd 5′-GAGTCAACGGATTTGGTCGT, GAPDH rev 5′-TTGGATTTGGAAGGATCTCG, CHRM1 fwd 5′-TGA CCGCTACTTCTCCGTGACT, CHRM1 rev 5′-CCAGA GCACAAAAGGGAACCA, PSA fwd 5′-GCATGGGAGTGGGATGAAGTAAG, PSA rev 5′-CATCAATACTGAGGTTGTCTGGGA, CTGF fwd 5′-GTGGCTGCTTCTCTAGCCTG, CYR61 fwd 5′-CAGGACTGTGAAGATTGC, CYR61 rev 5′-GCCCTGTAAGAGGGAAACGCT

**Western blotting**

Exponentially growing cells were washed in cold PBS, lysed on ice in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, Supplemented with Halt™ Protease and Phosphatase Inhibitor Cocktail (#78440, Thermo Fisher Scientific)). Cell extracts were collected, sonicated, and centrifuged to remove the cellular debris. Supernatants containing the solubilized proteins were quantified using the detergent compatible DC protein assay kit (#5000111, Bio-Rad, Hercules, CA, USA). Equal amounts of protein were separated by SDS-PAGE, and transferred to PVDF membranes. For immunodetection, membranes were blocked for 20 min at room temperature in 5% nonfat dry milk in TBST buffer, followed by 2 h incubation with the appropriate antibodies, in 3% BSA-T-TBS buffer. Detection was conducted by incubating the membranes with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (Southern Biotech, Birmingham, AL, USA) at a dilution of 1:20,000 in 5% milk-T-TBS buffer, at room temperature for 40 min, and visualized with Immobilon Western Chemiluminescent HRP Substrate (EMD Millipore, Burlington, MA, USA). The data were analyzed by ANOVA test or t test or Kaplan–Meier method or Fisher’s exact test. Asterisks denote statistical significance (nonsignificant or NS, P > 0.05; *P < 0.05; **P < 0.01; and ***P < 0.001). All data are reported as mean ± standard error of the mean (SEM). Sample sizes were chosen based on the historical data of the variability and response observed. The variance between the groups that are being statistically compared was similar.

**Acknowledgements**

YG is supported by the JSPS Overseas Research Fellowships and the Uehara Memorial Foundation Research Fellowship. XF is supported by 111 Project of MOE (B14038) China, the National Natural Science Foundation (81402230, 81672677) China. MG is supported by FIRC-AIRC fellowship for abroad (Italian Foundation for cancer research). We thank La Jolla Institute Microscopy Core Facility for professional advice and guidance, in particular Zbigniew Mikulski. This work was supported by S100D021831. YG initiated the study; YG and JSG designed the study and experiments; YG performed the genomic analyses; YG, TA, HI, NA, KA performed in vitro experiments, YG, NA and JSG provided advice and supervised the project. All authors discussed the results and reviewed the manuscript.

**Compliance with ethical standards**

**Conflict of interest** JSG is member of the Advisory Board of Oncocautics and Domain Therapeutics.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
2. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537–47.
3. Mauffrey P, Tchitchek N, Barroca V, Bemelmans A, Firlej V, Allory Y, et al. Progenitors from the central nervous system drive neurogenesis in cancer. Nature. 2019;569:672–8.
4. Zahalka AH, Arnal-Estape A, Maryanovich M, Nakahara F, Cruz CD, Finley LWS, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science. 2017;358:321–6.
5. Magnon C, Hall SJ, Lin J, Xue X, Gherber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.
6. Lee WY, Sun LM, Lin CL, Liang JA, Chang YJ, Sung FC, et al. Risk of prostate and bladder cancers in patients with spinal cord injury: a population-based cohort study. Urol Oncol. 2014;32: e151–7.
7. Patel N, Ngo K, Hastings J, Ketchum N, Sepahpanah F. Prevalence of prostate cancer in patients with chronic spinal cord injury. PM R. 2011;3:633–6.
8. Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65:635–41.
9. Kaye JA, Margulis AV, Fortuny J, McQuay LJ, Plana E, Bartsch JL, et al. Cancer incidence after initiation of antimuscarinic

SPRINGER NATURE
medications for overactive bladder in the united kingdom: evidence for protopathic bias. Pharmacotherapy. 2017;37:673–83.

10. Wang N, Yao M, Xu J, Quan Y, Zhang K, Yang R, et al. Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMK-mediated phosphorylation of Akt. Clin Cancer Res. 2015;21:4676–85.

11. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997;3:2493–2500.

12. Chlenski A, Nakashiro K, Ketels KV, Korovaietsa GI, Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate. 2001;47:66–75.

13. Gutkind JS, Novotny EA, Brann MR, Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA. 1991;88:4703–7.

14. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.

15. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA. 2007;104:5163–8.

16. Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, et al. The emerging mutational landscape of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA. 2007;104:5163–8.

17. Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeema H, Wang Z, et al. A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the Hippo pathway through FAK. Cancer Cell. 2019;35:457–72, e455.

18. O’Hayre M, Vazquez-Prado J, Kulfareva I, Stawiski EW, Handel TM, Seshagiri S, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer. 2013;13:412–24.

19. Wu V, Yeema H, Nohata N, Chiou J, Harisimendy O, Raimondi F, et al. Illuminating the Onco-GPCRome: novel G protein-coupled receptor-driven oncnicorne networks and targets for cancer immunotherapy. J Biol Chem. 2019;294:11062–86.

20. Menderatta P, Mostaghel E, Guiney J, Tewari AK, Porrello A, Barry WT, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009;27:2072–9.

21. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci USA. 2013;110: E4762–9.

22. Arora VK, Shenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to androgen-sensitive prostate cancer cell lines. Prostate. 2001;47:66–75.

23. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, et al. Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell. 2015;27:109–22.

24. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandrarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–86.

25. Blueman EG, Coleman JM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474–89, e476.

26. Mannan Baig A, Khan NA, Effendi V, Rana Z, Ahmad HR, Abbas F. Differential receptor dependencies: expression and significance of muscarinic M1 receptors in the biology of prostate cancer. Anti-Cancer Drugs. 2017;28:75–87.

27. Luthin GR, Wang P, Zhou H, Dhanasekaran D, Ruggieri MR. Role of m1 receptor-G protein coupling in cell proliferation in the prostate. Life Sci. 1997;60:963–8.

28. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mestub WK, Shah GV. Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate. 1997;30:160–6.

29. Daaka Y. G proteins in cancer: the prostate cancer paradigm. Science’s STKE. 2004;2004 re2.

30. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, et al. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2006;25:3719–34.

31. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the T3EAd-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26:1300–5.

32. Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B. YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun. 2015;6:8126.

33. Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, et al. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 2015;35:1350–62.

34. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 2004;137:683–96.

35. Gibaud F, Corvaisier M, Bully F, Huet G, Melnyk P, Cotelle P. Non-photoinduced biological properties of verteporfin. Curr Med Chem. 2016;23:1171–84.

36. Zhang H, Ramakrishnan SK, Triner D, Centofanti B, Maitra D, Gyorffy B, et al. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal. 2015;8:e498.

37. Konstantinou EK, Notomi S, Kosmidou C, Brodowska K, Al-Moujahed A, Nicolaou F, et al. Verteporfin-induced formation of protein cross-linked oligomers and high molecular weight complexes is mediated by light and leads to cell toxicity. Sci Rep. 2017;7:46581.

38. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008;68:1935–44.

39. Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther. 2009;8:2470–7.

40. Schultz A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs. 2010;19:777–88.

41. Sulzmaier FJ, Jean C, Schlaeffer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598–610.

42. Bankhead P, Loughrey MB, Fernandez JA, Dombrowsky Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.

43. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the eBioPortal. Sci Signal. 2013;6:pl1.